Stock listing
NASDAQ:NCEL NewcelX Ltd. Stock
Home listing (NASDAQ) of NewcelX Ltd.
Follow NewcelX Ltd. into a list and get an email when it puts out news.
Share price · NASDAQ:NCEL
$2.54 USD -0.11 (-4.2%)
Close on Nov 20, 2026
- Day range
- $2.45 – $2.63 USDNov 20, 2026
- Volume
- 5,608 sharesNov 20, 2026
- Market cap
- $14.67M USDAt the close on Nov 20, 2026 · price × 5.78M shares outstanding
- 52-week range
- $1.83 – $5.12 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $36,974 USDMedian day 7,200 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:NCEL · Home | $2.54 USD | -0.11 (-4.2%) | 5,608 | $2.63 | $2.63 | $2.45 | $2.65 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:NCEL · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $2.54 | -0.11 | -4.2% | $2.63 | $2.63 | $2.45 | 5,608 | |
| $2.65 | -0.03 | -1.1% | $2.70 | $2.70 | $2.64 | 4,291 | |
| $2.68 | -0.07 | -2.5% | $2.501 | $2.68 | $2.501 | 7,648 | |
| $2.75 | +0.14 | +5.4% | $2.61 | $2.75 | $2.61 | 6,399 | |
| $2.61 | -0.08 | -3.0% | $2.70 | $2.70 | $2.55 | 12,046 | |
| $2.69 | -0.11 | -3.9% | $2.92 | $2.975 | $2.69 | 12,215 | |
| $2.80 | -0.06 | -2.1% | $2.95 | $3.10 | $2.73 | 29,907 | |
| $2.86 | +0.08 | +2.9% | $2.86 | $2.892 | $2.68 | 24,395 | |
| $2.78 | +0.056 | +2.0% | $2.78 | $2.884 | $2.60 | 21,353 | |
| $2.724 | -0.166 | -5.7% | $2.80 | $2.80 | $2.645 | 11,156 | |
| $2.89 | +0.33 | +12.9% | $2.30 | $2.90 | $2.275 | 38,594 | |
| $2.56 | -0.08 | -3.0% | $2.45 | $2.67 | $2.34 | 275,030 | |
| $2.64 | +0.15 | +6.0% | $2.40 | $2.66 | $2.40 | 19,222 | |
| $2.49 | -0.06 | -2.4% | $2.551 | $2.57 | $2.36 | 11,343 | |
| $2.55 | -0.142 | -5.3% | $2.59 | $2.75 | $2.50 | 11,157 | |
| $2.692 | -0.008 | -0.3% | $2.70 | $2.73 | $2.648 | 1,701 | |
| $2.70 | -0.04 | -1.5% | $2.72 | $2.80 | $2.61 | 3,864 | |
| $2.74 | +0.19 | +7.5% | $2.59 | $2.80 | $2.59 | 12,390 | |
| $2.55 | -0.11 | -4.1% | $2.49 | $2.84 | $2.44 | 16,190 | |
| $2.66 | +0.10 | +3.9% | $2.53 | $2.76 | $2.49 | 10,400 | |
| $2.56 | -0.39 | -13.2% | $2.97 | $3.00 | $2.36 | 12,200 | |
| $2.95 | +0.34 | +13.0% | $2.59 | $3.04 | $2.59 | 11,900 | |
| $2.61 | -0.02 | -0.8% | $2.72 | $3.00 | $2.55 | 9,400 | |
| $2.63 | +0.13 | +5.2% | $2.90 | $2.90 | $2.53 | 5,400 | |
| $2.50 | -0.35 | -12.3% | $2.77 | $3.14 | $2.361 | 23,100 | |
| $2.85 | +0.24 | +9.2% | $2.61 | $2.90 | $2.61 | 5,900 | |
| $2.61 | -0.23 | -8.1% | $2.80 | $2.87 | $2.61 | 9,300 | |
| $2.84 | -0.064 | -2.2% | $2.83 | $3.279 | $2.80 | 5,400 | |
| $2.904 | -0.141 | -4.6% | $2.96 | $2.96 | $2.904 | 1,200 | |
| $3.045 | -0.065 | -2.1% | $3.02 | $3.082 | $3.02 | 1,300 | |
| $3.11 | +0.075 | +2.5% | $2.925 | $3.11 | $2.89 | 7,300 | |
| $3.035 | +0.074 | +2.5% | $3.04 | $3.04 | $2.975 | 1,500 | |
| $2.961 | +0.101 | +3.5% | $2.99 | $3.20 | $2.916 | 7,200 | |
| $2.86 | +0.01 | +0.4% | $2.824 | $2.86 | $2.82 | 4,100 | |
| $2.85 | -0.06 | -2.1% | $2.83 | $2.871 | $2.791 | 3,000 | |
| $2.91 | -0.165 | -5.4% | $2.82 | $2.95 | $2.76 | 5,200 | |
| $3.075 | +0.105 | +3.5% | $3.22 | $3.25 | $3.00 | 2,700 | |
| $2.97 | +0.05 | +1.7% | $2.85 | $2.97 | $2.79 | 3,100 | |
| $2.92 | -0.027 | -0.9% | $2.87 | $3.02 | $2.76 | 7,200 | |
| $2.947 | +0.057 | +2.0% | $2.99 | $3.21 | $2.947 | 4,800 | |
| $2.89 | +0.03 | +1.0% | $2.89 | $2.90 | $2.76 | 4,200 | |
| $2.86 | -0.176 | -5.8% | $2.91 | $3.09 | $2.758 | 9,300 | |
| $3.036 | +0.066 | +2.2% | $2.96 | $3.37 | $2.90 | 4,700 | |
| $2.97 | -0.18 | -5.7% | $3.23 | $3.243 | $2.90 | 12,300 | |
| $3.15 | -0.23 | -6.8% | $3.158 | $3.38 | $3.13 | 2,500 | |
| $3.38 | -0.01 | -0.3% | $3.295 | $3.39 | $3.15 | 12,200 | |
| $3.39 | +0.07 | +2.1% | $3.293 | $3.40 | $3.14 | 4,600 | |
| $3.32 | +0.04 | +1.2% | $3.35 | $3.35 | $3.31 | 2,800 | |
| $3.28 | -0.025 | -0.8% | $3.28 | $3.31 | $3.225 | 6,800 | |
| $3.305 | -0.075 | -2.2% | $3.30 | $3.324 | $3.224 | 3,700 | |
| $3.38 | +0.13 | +4.0% | $3.29 | $3.50 | $3.25 | 5,700 | |
| $3.25 | 0.00 | 0.0% | $3.16 | $3.30 | $3.16 | 3,500 | |
| $3.25 | -0.10 | -3.0% | $3.235 | $3.35 | $3.22 | 4,200 | |
| $3.35 | 0.00 | 0.0% | $3.37 | $3.37 | $3.24 | 1,400 | |
| $3.35 | 0.00 | 0.0% | $3.458 | $3.50 | $3.147 | 9,000 | |
| $3.35 | +0.06 | +1.8% | $3.39 | $3.39 | $3.33 | 3,500 | |
| $3.29 | +0.015 | +0.5% | $3.21 | $3.29 | $3.21 | 1,900 | |
| $3.275 | +0.085 | +2.7% | $3.40 | $3.40 | $3.23 | 13,900 | |
| $3.19 | -0.23 | -6.7% | $3.37 | $3.37 | $3.19 | 12,400 | |
| $3.42 | +0.04 | +1.2% | $3.27 | $3.51 | $3.27 | 20,000 | |
| $3.38 | -0.10 | -2.9% | $3.44 | $3.514 | $3.30 | 18,700 | |
| $3.48 | +0.02 | +0.6% | $3.50 | $3.60 | $3.31 | 17,000 | |
| $3.46 | +0.197 | +6.0% | $3.40 | $3.50 | $3.325 | 6,100 | |
| $3.263 | -0.107 | -3.2% | $3.31 | $3.31 | $3.215 | 1,400 | |
| $3.37 | +0.12 | +3.7% | $3.25 | $3.40 | $3.17 | 9,200 |
Splits
2 splits since 2024 · NASDAQ:NCEL · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-10 | Consolidation | |
| 1-for-40 | Consolidation |
- Ticker
- NASDAQ:NCEL
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 9, 2026
NewcelX Announces Pricing of $1.55 Million Equity Financing at 20% Premium Pricing to Market
Latest deck · Apr 20, 2026
Investor Presentation (April 2026)
Investor deck · 27 slides
Latest news
NewcelX Announces Pricing of $1.55 Million Equity Financing at 20% Premium Pricing to Market
Nov 9, 2026
Closed $2.78 (+2.0%) on Nov 9, 2026
NewcelX Enters into Binding Term Sheet to Divest Legacy Mazindol Portfolio (CVR), Providing for Upfront Cash, Equity Ownership and Up to $55 Million in Potential Milestone Payments
Nov 4, 2026
Closed $2.56 (-3.0%) on Nov 4, 2026
NewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a Cure for Type 1 Diabetes
Sep 28, 2026
Closed $2.92 (-0.9%) on Sep 28, 2026
NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing
Jul 31, 2026
Closed $3.49 (+3.8%) on Jul 31, 2026
NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board
Jul 8, 2026
Closed $4.23 (+5.5%) on Jul 8, 2026
NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology Platform
Jun 15, 2026
Closed $3.20 (-0.9%) on Jun 15, 2026
NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes
May 27, 2026
Closed $3.45 (+9.5%) on May 27, 2026
NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026
Apr 30, 2026
Closed $4.41 (+28.9%) on Apr 30, 2026
NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference
Apr 20, 2026
Closed $2.83 (+6.4%) on Apr 20, 2026
NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing
Apr 1, 2026
Closed $2.35 (+10.8%) on Apr 1, 2026
NewcelX Ltd. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 16 in the last 12 months · 21 in all · newest Nov 9, 2026 · oldest 2025
- Decks
- 9 decks · latest Apr 20, 2026
Where NewcelX Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:NCEL · Home listing · This page | NASDAQ | United States | USD |
| BOATS:NCEL | BOATS | United States | USD |
Valuation
Price/book 2.4× against a median of 0.7×: 6th lowest of 7 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $14.35M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.4×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 0.89
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| NewcelX Ltd. · NASDAQ:NCEL | US$14.67M | US$14.35M | n/a | n/a | n/a | 2.4× | n/a | 0.1× | 0.89 |
| Quoin Pharmaceuticals. Ltd · NASDAQ:QNRX | US$15.76M | −US$17.43M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | 0.68 |
| Celularity Inc. · NASDAQ:CELU | US$15.02M | US$50.46M | n/a | 2.7× | n/a | n/a | −117.3% | n/a | 1.47 |
| Context Therapeutics Inc. · NASDAQ:CNTX | US$14.70M | −US$19.50M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | 0.99 |
| Hepion Pharmaceuticals, Inc. · OTC:HEPA | US$14.63M | US$10.37M | n/a | n/a | n/a | n/a | n/a | n/a | -1.02 |
| Vectorite Biomedical, Inc. · TPEX:4170 | US$14.21M | US$9.16M | 4.9× | 4.9× | n/a | 0.9× | 156.6% | 0.0× | n/a |
| Estrella Immunopharma, Inc. · NASDAQ:ESLA | US$14.11M | US$14.01M | n/a | n/a | n/a | n/a | n/a | n/a | 1.31 |
| Citius Pharmaceuticals, Inc. · NASDAQ:CTXR | US$13.96M | −US$3.05M | n/a | n/a | n/a | 0.2× | n/a | 0.0× | 1.71 |
| TaiwanJ Pharmaceuticals Co., Ltd. · TPEX:6549 | US$13.69M | US$11.86M | n/a | n/a | n/a | 7.0× | n/a | 0.0× | n/a |
| Actuate Therapeutics, Inc. · NASDAQ:ACTU | US$13.60M | US$11.50M | n/a | n/a | n/a | n/a | n/a | n/a | 1.75 |
| BeyondSpring, Inc. · NASDAQ:BYSI | US$13.57M | US$12.99M | 0.3× | n/a | n/a | 0.9× | n/a | 0.0× | 1.31 |
| Median of the others | US$14.16M | US$10.94M | 2.6× | 3.8× | 0.7× | 19.6% | 0.0× | 1.31 |
Forecasts
1 buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 23.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.18 · 1 analyst
Team and board
| Officer | Role |
|---|---|
| Jeremy Shefner | PhD, Chief Medical Officer |
| Julien Boisdron | Chief Medical Officer of a Swiss Big Pharma |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2025 | Oct 6, 2025 | −8.3% |
| Q2 2025 | Aug 31, 2025 | −2.8% |
| Q1 2025 | May 16, 2025 | +6.2% |
| Q3 2024 | Oct 18, 2024 | −8.1% |
| Q1 2023 | May 5, 2023 | +5.4% |
| Q3 2022 | Oct 11, 2022 | −4.6% |
| Q4 2021 | Mar 24, 2022 | +3.7% |
| Q2 2021 | Sep 28, 2021 | −1.2% |
| Q1 2021 | May 14, 2021 | +5.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (April 2026) | Investor deck | 27 slides | Apr 20, 2026 |
| Investor Presentation (January 2026) | Investor deck | 27 slides | Jan 29, 2026 |
| Investor Presentation (November 2025) | Investor deck | 43 slides | Nov 3, 2025 |
| NLS Pharmaceutics — Investor Presentation (September 2023) | Investor deck | 49 slides | Sep 13, 2023 |
| NLS Pharmaceutics — Corporate Update (July 2023) | Corporate update | 41 slides | Jul 20, 2023 |
| NLS Pharmaceutics — Investor Presentation (February 2023) | Investor deck | 33 slides | Feb 1, 2023 |
| NLS Pharmaceutics — Investor Presentation (April 2022) | Investor deck | 30 slides | Apr 6, 2022 |
| NLS Pharmaceutics — Investor Presentation (July 2021) | Investor deck | 29 slides | Jul 6, 2021 |
| NLS Pharmaceutics — Investor Presentation (April 2021) | Investor deck | 26 slides | Apr 6, 2021 |
Financings
| Raise | Date |
|---|---|
| Private placement of private placement with warrants Closed: US$1.35M raised | Apr 30, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as NLS Pharmaceutics Ltd. Priced at US$4.15 a unit on Jan 28, 2021.
- Price
- US$4.15 a unit
- Units offered
- 4,819,277 units
- Offering size
- US$20 million
- Underwriters' option
- Up to 722,891 more units
- Listing
- NLSP on the Nasdaq Capital Market
- Underwriters
- Maxim Group LLC, Brookline Capital Markets · In the order on the cover
- Units delivered
- On or about Feb 2, 2021
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Dec 18, 2019 |
| Filed publicly | Feb 28, 2020 |
| Amended 5 times | Newest Jan 20, 2021 |
| Shares registered with an exchange | Jan 28, 2021 |
| Declared effective by the SEC | Jan 28, 2021 |
| Final prospectus, with the price | Feb 1, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Feb 1, 2021 |
| EFFECT · Notice that a registration is effective | Jan 28, 2021 |
| CERT · Exchange's certificate of listing | Jan 28, 2021 |
| CERT · Exchange's certificate of listing | Jan 28, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Jan 28, 2021 |
| CORRESP · Letter to the SEC | Jan 25, 2021 |
| CORRESP · Letter to the SEC | Jan 25, 2021 |
| F-1/A · Registration statement, amended | Jan 20, 2021 |
| CORRESP · Letter to the SEC | Nov 19, 2020 |
| F-1/A · Registration statement, amended | Nov 17, 2020 |
All 23 filings
| Filing | Filed |
|---|---|
| UPLOAD · Letter from the SEC | Nov 17, 2020 |
| F-1/A · Registration statement, amended | Nov 13, 2020 |
| CORRESP · Letter to the SEC | Oct 19, 2020 |
| F-1/A · Registration statement, amended | Oct 19, 2020 |
| UPLOAD · Letter from the SEC | Sep 17, 2020 |
| CORRESP · Letter to the SEC | Aug 31, 2020 |
| F-1/A · Registration statement, amended | Aug 31, 2020 |
| UPLOAD · Letter from the SEC | Mar 3, 2020 |
| F-1 · Registration statement | Feb 28, 2020 |
| DRSLTR · Letter to the SEC with a draft | Feb 20, 2020 |
| DRS/A · Draft registration statement, amended | Feb 20, 2020 |
| UPLOAD · Letter from the SEC | Jan 15, 2020 |
| DRS · Draft registration statement | Dec 18, 2019 |
Open IPO · From the cover of the final prospectus (424B4) filed Feb 1, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | ||||||||
| Research and development | 1.13M | 992.0K | 1.61M | 8.98M | 5.92M | 99.6K | 897.8K | 708.5K | 4.32M |
| Selling, general and administrative | 1.35M | 2.20K | 3.30M | 2.74K | 1.44M | ||||
| Operating income | -2.56M | -2.07M | -3.02M | -15.5M | -11.9M | -2.30M | -4.20M | -3.45M | -5.77M |
| Depreciation and amortization | 55.0K | 413.0K | 620.0K | 11.4K | 10.1K | 72.2M | 311 | 116 | 191 |
| EBITDA | -2.51M | -1.65M | -2.40M | -15.5M | -11.9M | 69.9M | -4.20M | -3.45M | -5.77M |
| Interest expense | 6.01M | 45.1K | 119.9K | 95.2K | 48.1K | 86.8K | 992 | 1.08K | 890.4K |
| Income before tax | -8.30M | -7.20M | -3.28M | -2.86M | -5.45M | -5.15K | -6.66M | ||
| Income tax | -5.77K | ||||||||
| Net income | -8.30M | -7.20M | -3.33M | -16.5M | -11.9M | -2.86M | -5.45M | -5.15M | -6.66M |
| Earnings per share, basic | 2.16 | 2.43 | 1.13 | -33.52 | -1.00 | -0.41 | -0.78 | -0.32 | -5.65 |
| Earnings per share, diluted | 2.16 | 2.43 | 1.13 | -33.52 | -1.00 | -0.41 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 2.20M | 650.0K | 1.15M | 8.95M | 5.43M | 93.7K | 220.3K | 6.68K | 2.18M |
| Receivables | 61.2K | 75.4K | 36.9K | ||||||
| Inventory | -61.2K | -9.36K | |||||||
| Current assets | 3.18M | 780.0K | 1.82M | 9.25M | 5.72M | 196.7K | 381.7K | 90.2K | 2.27M |
| Property, plant and equipment | 95.0K | 123.0K | 6.69K | 18.1K | 29.5K | ||||
| Goodwill | 1.73M | ||||||||
| Total assets | 11.4M | 903.0K | 1.85M | 9.28M | 5.76M | 1.21M | 696.4K | 145.6K | 2.29M |
| Accounts payable | 1.92M | 515.5K | 4.63M | 2.37M | 1.74M | 4.01M | 2.51M | 1.13M | 565.0K |
| Current liabilities | 4.20M | 8.90M | 7.92M | 3.36M | 2.40M | 7.20M | 4.04M | 2.41M | 990.0K |
| Total debt | 355.0K | 263.1K | 842.1K | 7.09M | 8.87M | ||||
| Total liabilities | 4.20M | 8.90M | 10.7M | 6.00M | 5.22M | 10.2M | 6.87M | 8.96M | 10.0M |
| Shareholders' equity | 7.25M | -8.00M | -1.20M | 111.0K | 542.4K | -8.98M | -6.17M | -8.81M | -7.72M |
| Shares outstanding | 4.80M | 2.96M | 810.7K | 32.4M | 16.2M | 6.96M | 6.96M | 16.2M | 1.18M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -2.77M | -1.07M | -3.44M | -13.9M | -14.9M | -729.4K | -190.0K | -2.73M | -5.43M |
| Capital spending | -8.00K | -6.00K | -6.00K | -39.6K | -4 | 0 | 0 | 0 | |
| Free cash flow | -2.77M | -1.07M | -3.45M | -15.0M | -729.4K | -190.0K | -2.73M | -5.43M | |
| Cash from investing | 1.70M | -6.00K | 103.0K | -39.6K | 225.6K | -217.3K | |||
| Cash from financing | 2.63M | 450.0K | 2.85M | 17.4M | 20.3M | 503.5K | 407.5K | 557.9K | 6.73M |
| Change in cash | 1.55M | -666.0K | -658.0K | 3.52M | 5.34M | -126.6K | 213.6K | -2.18M | 1.30M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| D | Nov 18, 2026 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Nov 9, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 9, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 4, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Sep 23, 2026 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Sep 18, 2026 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Sep 18, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Aug 27, 2026 | Other filings | SEC |
| D | Aug 24, 2026 | Other filings | SEC |
| F-3 · Registration statement | Aug 20, 2026 | Offer document | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 6-K · Report of a foreign issuer | Aug 3, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jul 31, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jul 15, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jul 8, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jul 1, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jun 30, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Jun 18, 2026 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Jun 15, 2026 | Current report | SEC |
| F-3/A · Registration statement, amended | Jun 10, 2026 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Jun 5, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | May 27, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | May 18, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 14, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 14, 2026 | Other filings | SEC |
| D | May 12, 2026 | Other filings | SEC |
| F-3 · Registration statement | May 11, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | May 7, 2026 | Other filings | SEC |
| POS AM · Amendment to an effective registration | May 5, 2026 | Offer document | SEC |
| SCHEDULE 13D · Big-stake notice | May 4, 2026 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Apr 30, 2026 | Current report | SEC |
| 20-F · Annual report | Apr 29, 2026 | Annual report | SEC |
| 4 · Change in ownership | Apr 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 29, 2026 | Insider trade | SEC |
| 6-K · Report of a foreign issuer | Apr 20, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Apr 1, 2026 | Current report | SEC |
| 3 · Initial statement of ownership | Mar 18, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 18, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 18, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 18, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 18, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 18, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 18, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 18, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 18, 2026 | Insider trade | SEC |
| 6-K · Report of a foreign issuer | Mar 9, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Feb 12, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jan 29, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jan 12, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jan 5, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Dec 11, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 20, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Nov 19, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Nov 19, 2025 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Nov 17, 2025 | Current report | SEC |
| SCHEDULE 13D · Big-stake notice | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D · Big-stake notice | Nov 13, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 13, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 7, 2025 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Nov 7, 2025 | Current report | SEC |
| POS AM · Amendment to an effective registration | Nov 5, 2025 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 4, 2025 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Nov 4, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 3, 2025 | Current report | SEC |
| 25-NSE/A | Oct 30, 2025 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Oct 30, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 30, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 29, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 28, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 28, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 27, 2025 | Current report | SEC |
| POS AM · Amendment to an effective registration | Oct 24, 2025 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Oct 23, 2025 | Current report | SEC |
| POS AM · Amendment to an effective registration | Oct 17, 2025 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Oct 9, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 3, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Oct 1, 2025 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Sep 30, 2025 | Current report | SEC |
| CORRESP · Letter to the SEC | Sep 29, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 29, 2025 | Other filings | SEC |
| F-1 · Registration statement | Sep 25, 2025 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Sep 19, 2025 | Current report | SEC |
| 424B3 · Prospectus | Sep 10, 2025 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Sep 10, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Sep 10, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 8, 2025 | Other filings | SEC |
| 425 | Sep 4, 2025 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Sep 4, 2025 | Current report | SEC |
| CORRESP · Letter to the SEC | Sep 3, 2025 | Other filings | SEC |
| F-4/A | Sep 3, 2025 | Offer document | SEC |
| 425 | Aug 29, 2025 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Aug 29, 2025 | Current report | SEC |
| UPLOAD · Letter from the SEC | Aug 28, 2025 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Aug 25, 2025 | Current report | SEC |
| CORRESP · Letter to the SEC | Aug 15, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 6, 2025 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Aug 6, 2025 | Current report | SEC |
| F-4/A | Jul 29, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jul 29, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 23, 2025 | Other filings | SEC |
| F-4/A | Jul 18, 2025 | Offer document | SEC |
| 425 | Jul 18, 2025 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Jul 18, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jul 17, 2025 | Current report | SEC |
| D | Jul 10, 2025 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Jul 1, 2025 | Current report | SEC |
| 425 | Jul 1, 2025 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Jul 1, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jun 30, 2025 | Current report | SEC |
| SCHEDULE 13D · Big-stake notice | Jun 24, 2025 | Big-stake notice | SEC |
| CORRESP · Letter to the SEC | Jun 23, 2025 | Other filings | SEC |
| F-4/A | Jun 23, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Jun 18, 2025 | Other filings | SEC |
| 425 | Jun 16, 2025 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Jun 16, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jun 10, 2025 | Current report | SEC |
| CORRESP · Letter to the SEC | Jun 9, 2025 | Other filings | SEC |
| F-4/A | Jun 9, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jun 9, 2025 | Other filings | SEC |
| 425 | Jun 6, 2025 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Jun 6, 2025 | Current report | SEC |
| 20-F · Annual report | May 16, 2025 | Annual report | SEC |
| 6-K · Report of a foreign issuer | May 5, 2025 | Current report | SEC |
| NT 20-F | May 1, 2025 | Explanation request | SEC |
| 6-K · Report of a foreign issuer | Apr 24, 2025 | Current report | SEC |
| UPLOAD · Letter from the SEC | Apr 15, 2025 | Other filings | SEC |
| 425 | Apr 15, 2025 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Apr 15, 2025 | Current report | SEC |
| D | Apr 14, 2025 | Other filings | SEC |
| 6-K/A · Report of a foreign issuer, amended | Apr 4, 2025 | Current report | SEC |
| CORRESP · Letter to the SEC | Mar 31, 2025 | Other filings | SEC |
| F-4/A | Mar 31, 2025 | Offer document | SEC |
| 425 | Mar 31, 2025 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Mar 31, 2025 | Current report | SEC |
| UPLOAD · Letter from the SEC | Mar 20, 2025 | Other filings | SEC |
| 425 | Mar 10, 2025 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Mar 10, 2025 | Current report | SEC |
| F-4/A | Mar 3, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Feb 28, 2025 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Feb 27, 2025 | Current report | SEC |
| 425 | Feb 25, 2025 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Feb 25, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| F-3 · Registration statement | Feb 10, 2025 | Offer document | SEC |
| 425 | Feb 10, 2025 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Feb 10, 2025 | Current report | SEC |
| F-3 · Registration statement | Feb 5, 2025 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Jan 31, 2025 | Current report | SEC |
| 425 | Jan 31, 2025 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Jan 31, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jan 30, 2025 | Current report | SEC |
| 425 | Jan 28, 2025 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Jan 28, 2025 | Current report | SEC |
| UPLOAD · Letter from the SEC | Jan 27, 2025 | Other filings | SEC |
| D | Jan 22, 2025 | Other filings | SEC |
| 425 | Jan 16, 2025 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Jan 16, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jan 14, 2025 | Current report | SEC |
| 425 | Jan 8, 2025 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Jan 8, 2025 | Current report | SEC |
| 6-K · Report of a foreign issuer | Jan 7, 2025 | Current report | SEC |
| 425 | Dec 30, 2024 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Dec 30, 2024 | Current report | SEC |
| F-4 | Dec 30, 2024 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Dec 23, 2024 | Current report | SEC |
| 6-K/A · Report of a foreign issuer, amended | Dec 19, 2024 | Current report | SEC |
| 425 | Dec 19, 2024 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Dec 19, 2024 | Current report | SEC |
| 6-K · Report of a foreign issuer | Dec 17, 2024 | Current report | SEC |
| 425 | Dec 11, 2024 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Dec 11, 2024 | Current report | SEC |
| 6-K/A · Report of a foreign issuer, amended | Dec 10, 2024 | Current report | SEC |
| 6-K · Report of a foreign issuer | Dec 4, 2024 | Current report | SEC |
| 6-K · Report of a foreign issuer | Dec 3, 2024 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Nov 27, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 25, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 21, 2024 | Big-stake notice | SEC |
| CORRESP · Letter to the SEC | Nov 18, 2024 | Other filings | SEC |
| F-3/A · Registration statement, amended | Nov 18, 2024 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Nov 18, 2024 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 15, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Nov 12, 2024 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 8, 2024 | Current report | SEC |
| 6-K · Report of a foreign issuer | Nov 6, 2024 | Current report | SEC |
| 425 | Nov 5, 2024 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Nov 5, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 4, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 4, 2024 | Big-stake notice | SEC |
| 425 | Nov 4, 2024 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Nov 4, 2024 | Current report | SEC |
| UPLOAD · Letter from the SEC | Nov 1, 2024 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Oct 28, 2024 | Current report | SEC |
| F-3 · Registration statement | Oct 23, 2024 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Oct 22, 2024 | Current report | SEC |
| D | Oct 21, 2024 | Other filings | SEC |
| 6-K · Report of a foreign issuer | Oct 18, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Oct 15, 2024 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Oct 15, 2024 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 11, 2024 | Current report | SEC |
This page holds 200 of 420 filings. Open Filings
Cap table
Built by 6ix from NewcelX Ltd.’s releases · as of Apr 30, 2026
- Common shares
- 5,776,128
- Fully diluted
- 5,776,128
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 5,776,128 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 5,776,128 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Alexander Zwyer | Director · Since at least Mar 18, 2026 |
| Eran Israel Iohan | Director · Since at least Mar 18, 2026 |
| Jeremy Shefner | PhD, Chief Medical Officer · Since at least Nov 17, 2025 |
| Julien Boisdron | Chief Medical Officer of a Swiss Big Pharma · Since at least Apr 30, 2026 |
| Kfir Molakandov | VP of R&D · Since at least Mar 18, 2026 |
| Liora Oren | Director · Since at least Mar 18, 2026 |
| Michel Revel | CSO and Director, Director · Since at least Mar 18, 2026 |
| Olivier Samuel | Director · Since at least Mar 18, 2026 |
| Omri Hagai | Chief Financial Officer · Since at least Mar 18, 2026 |
| Ronen Twito | Chairman and CEO, Director · Since at least Mar 18, 2026 |
All 11 people
| Person | Seat |
|---|---|
| Tamar Galili | Director · Since at least Mar 18, 2026 |
Log in to ask 6ix AI your own questions about NewcelX Ltd.